Retinopathy of Prematurity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 67 pages | ID: R82664C11BBAEN
Global Markets Direct

Abstracts

Retinopathy of Prematurity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Drugs In Development, 2022, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinopathy Of Prematurity - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 4, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Retinopathy Of Prematurity - Overview
Retinopathy Of Prematurity - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Retinopathy Of Prematurity - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
Retinopathy Of Prematurity - Drug Profiles
Retinopathy Of Prematurity - Dormant Projects
Retinopathy Of Prematurity - Product Development Milestones
Featured News & Press Releases
Nov 10, 2021: Bayer submits Aflibercept for regulatory approval in the EU and Japan for retinopathy of prematurity in premature babies
Nov 22, 2019: Novartis gets Lucentis approval for additional indication for retinopathy of prematurity, a rare disease that can lead to blindness in children
Jul 26, 2019: Novartis receives positive CHMP opinion for Lucentis treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness
Mar 11, 2019: Bascom Palmer’s Dr. Wei Li awarded $9.12 million NEI grant
Sep 22, 2018: Novartis to file for new Lucentis (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Retinopathy Of Prematurity, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Retinopathy Of Prematurity - Pipeline by ANBITION Srl, 2022
Retinopathy Of Prematurity - Pipeline by Anida Pharma Inc, 2022
Retinopathy Of Prematurity - Pipeline by AntlerA Therapeutics Inc, 2022
Retinopathy Of Prematurity - Pipeline by Ayuvis Research Inc, 2022
Retinopathy Of Prematurity - Pipeline by D. Western Therapeutics Institute Inc, 2022
Retinopathy Of Prematurity - Pipeline by Drive Therapeutics LLC, 2022
Retinopathy Of Prematurity - Pipeline by Elgan Pharma Ltd, 2022
Retinopathy Of Prematurity - Pipeline by Everglades Biopharma LLC, 2022
Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Retinopathy Of Prematurity - Pipeline by Insmed Inc, 2022
Retinopathy Of Prematurity - Pipeline by Kowa Co Ltd, 2022
Retinopathy Of Prematurity - Pipeline by Novelty Nobility Inc, 2022
Retinopathy Of Prematurity - Pipeline by Orphanix GmbH, 2022
Retinopathy Of Prematurity - Pipeline by Pamdeca LLC, 2022
Retinopathy Of Prematurity - Pipeline by Recordati Rare Diseases Inc, 2022
Retinopathy Of Prematurity - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Retinopathy Of Prematurity - Pipeline by Shenzhen Evergreen Therapeutics Co Ltd, 2022
Retinopathy Of Prematurity - Pipeline by Signablok Inc, 2022
Retinopathy Of Prematurity - Pipeline by Worphmed Srl, 2022
Retinopathy Of Prematurity - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Retinopathy Of Prematurity, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022